Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP
Founder-led company
Tonix Pharmaceuticals Holding Corp. stock price today
$35.59
+35.25
+10442.06%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Tonix Pharmaceuticals Holding Corp. stock price monthly change
-43.79%
month
Tonix Pharmaceuticals Holding Corp. stock price quarterly change
-43.79%
quarter
Tonix Pharmaceuticals Holding Corp. stock price yearly change
-18.55%
year
Tonix Pharmaceuticals Holding Corp. key metrics
Market Cap | 85.76M |
Enterprise value | N/A |
P/E | -0.17 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.10 |
PEG ratio | N/A |
EPS | -5.15 |
Revenue | N/A |
EBITDA | -103.41M |
Income | -98.59M |
Revenue Q/Q | -92.67% |
Revenue Y/Y | -80.53% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTonix Pharmaceuticals Holding Corp. stock price history
Tonix Pharmaceuticals Holding Corp. stock forecast
Tonix Pharmaceuticals Holding Corp. financial statements
| Jun 2023 | 0 | -28.35M | |
|---|---|---|---|
| Sep 2023 | 3.98M | -27.97M | -701.3% |
| Dec 2023 | 3.77M | -27.32M | -723% |
| Mar 2024 | 2.48M | -14.93M | -601.89% |
| Sep 2025 | 7.8M | -4.12M | -52.93% |
|---|---|---|---|
| Oct 2025 | 4.65M | -452.92M | -9740.28% |
| Dec 2025 | 8.1M | -2.29M | -28.38% |
| Dec 2025 | 5.02M | -439.98M | -8755.87% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 0.71% |
| 2021 | |
| 2022 | 46.79% |
| 2023 |
| Jun 2023 | 159736000 | 19.27M | 12.07% |
|---|---|---|---|
| Sep 2023 | 139282000 | 18.44M | 13.25% |
| Dec 2023 | 154457000 | 48.93M | 31.68% |
| Mar 2024 | 135343000 | 27.2M | 20.1% |
| Jun 2023 | -23.36M | -24.01M | 1.02M |
|---|---|---|---|
| Sep 2023 | -23.38M | -821K | 6.27M |
| Dec 2023 | -21.68M | -98.60K | 41.28M |
| Mar 2024 | -17.57M | -108K | -212K |
Tonix Pharmaceuticals Holding Corp. alternative data
| Sep 2023 | 117 |
|---|---|
| Oct 2023 | 117 |
| Nov 2023 | 117 |
| Dec 2023 | 117 |
| Jan 2024 | 117 |
| Feb 2024 | 117 |
| Mar 2024 | 117 |
| Apr 2024 | 117 |
| May 2024 | 103 |
| Jun 2024 | 103 |
| Jul 2024 | 103 |
Tonix Pharmaceuticals Holding Corp. other data
24.39%
-2.18%
of TNXP is owned by hedge funds
22
-13
5.46M
+1.13M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2021 | 12000 | 0 |
| Mar 2022 | 100000 | 0 |
| Jun 2022 | 20000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LEDERMAN SETH director, officer.. | Common Stock, $0.001 par value | 20,000 | $1.71 | $34,200 | ||
Purchase | LEDERMAN SETH director, officer.. | Common Stock, $0.001 par value | 100,000 | $0.25 | $24,500 | ||
Purchase | LEDERMAN SETH director, officer.. | Common Stock, $0.001 par value | 12,000 | $0.61 | $7,320 | ||
Purchase | GOODMAN DANIEL WINTNER director | Common Stock | 5,000 | N/A | N/A | ||
Purchase | LEDERMAN SETH director, officer.. | Common Stock, $0.001 par value | 16,733 | $1.32 | $22,088 | ||
Purchase | LEDERMAN SETH director, officer.. | Common Stock, $0.001 par value | 35,000 | $0.68 | $23,800 | ||
Purchase | TRECO JAMES director | Common Stock, par value $0.001 | 5,500 | $0.89 | $4,895 | ||
Purchase | BELL MARGARET SMITH director | Common Stock, par value $0.001 | 5,391 | $0.93 | $4,997 | ||
Purchase | SULLIVAN GREGORY M officer: Chief Me.. | Common Stock, par value $0.001 | 20,000 | $1.03 | $20,600 | ||
Purchase | TRECO JAMES director | Common Stock, par value $0.001 | 4,500 | $1.06 | $4,770 |
| Patent |
|---|
Application Filling date: 13 Apr 2020 Issue date: 16 Jun 2022 |
Application Filling date: 22 Oct 2021 Issue date: 28 Apr 2022 |
Application Filling date: 16 Jul 2021 Issue date: 20 Jan 2022 |
Application Filling date: 7 May 2021 Issue date: 16 Dec 2021 |
Application Filling date: 8 Apr 2021 Issue date: 14 Oct 2021 |
Application Filling date: 26 Feb 2021 Issue date: 26 Aug 2021 |
Application Filling date: 13 Jul 2018 Issue date: 23 Jul 2020 |
| Insider | Compensation |
|---|---|
| Dr. Seth Lederman (1958) Co-Founder, Pres, Chief Executive Officer & Chairman | $1,070,000 |
| Dr. Gregory M. Sullivan M.D. (1966) Chief Medical Officer & Sec. | $676,200 |
Mr. Bradley Saenger CPA, CPA (1974) Chief Financial Officer & Treasurer | $586,160 |
-
What's the price of Tonix Pharmaceuticals Holding Corp. stock today?
One share of Tonix Pharmaceuticals Holding Corp. stock can currently be purchased for approximately $35.59.
-
When is Tonix Pharmaceuticals Holding Corp.'s next earnings date?
Unfortunately, Tonix Pharmaceuticals Holding Corp.'s (TNXP) next earnings date is currently unknown.
-
Does Tonix Pharmaceuticals Holding Corp. pay dividends?
No, Tonix Pharmaceuticals Holding Corp. does not pay dividends.
-
How much money does Tonix Pharmaceuticals Holding Corp. make?
Tonix Pharmaceuticals Holding Corp. has a market capitalization of 85.76M.
-
What is Tonix Pharmaceuticals Holding Corp.'s stock symbol?
Tonix Pharmaceuticals Holding Corp. is traded on the NASDAQ under the ticker symbol "TNXP".
-
What is Tonix Pharmaceuticals Holding Corp.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Tonix Pharmaceuticals Holding Corp.?
Shares of Tonix Pharmaceuticals Holding Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Tonix Pharmaceuticals Holding Corp.'s key executives?
Tonix Pharmaceuticals Holding Corp.'s management team includes the following people:
- Dr. Seth Lederman Co-Founder, Pres, Chief Executive Officer & Chairman(age: 67, pay: $1,070,000)
- Dr. Gregory M. Sullivan M.D. Chief Medical Officer & Sec.(age: 59, pay: $676,200)
- Mr. Bradley Saenger CPA, CPA Chief Financial Officer & Treasurer(age: 51, pay: $586,160)
-
Is Tonix Pharmaceuticals Holding Corp. founder-led company?
Yes, Tonix Pharmaceuticals Holding Corp. is a company led by its founder Dr. Seth Lederman.
-
How many employees does Tonix Pharmaceuticals Holding Corp. have?
As Jul 2024, Tonix Pharmaceuticals Holding Corp. employs 103 workers, which is 12% less then previous quarter.
-
When Tonix Pharmaceuticals Holding Corp. went public?
Tonix Pharmaceuticals Holding Corp. is publicly traded company for more then 13 years since IPO on 10 May 2012.
-
What is Tonix Pharmaceuticals Holding Corp.'s official website?
The official website for Tonix Pharmaceuticals Holding Corp. is tonixpharma.com.
-
Where are Tonix Pharmaceuticals Holding Corp.'s headquarters?
Tonix Pharmaceuticals Holding Corp. is headquartered at 26 Main Street, Chatham, NJ.
-
How can i contact Tonix Pharmaceuticals Holding Corp.?
Tonix Pharmaceuticals Holding Corp.'s mailing address is 26 Main Street, Chatham, NJ and company can be reached via phone at +86 27998599.
Tonix Pharmaceuticals Holding Corp. company profile:
Tonix Pharmaceuticals Holding Corp.
tonixpharma.comExchange:
NASDAQ
Full time employees:
103
Industry:
Biotechnology
Sector:
Healthcare
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
26 Main Street
Chatham, NJ 07928
Chatham, NJ 07928
CIK: 0001430306
ISIN: US8902608541
CUSIP: 890260862
